China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
29/07/26	$0.0576	-17.48%	61,789,396
27/07/26	$0.0698	+9.40%	340,438,249
24/07/26	$0.0638	-80.82%	324,050,297
23/07/26	$0.3326	-83.53%	64,028,733
22/07/26	$2.020	-24.63%	26,499,591

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 00:00:00 29/07/2026 +04			5-day change	1st Jan Change
0.0576 ^USD	-17.48%		-97.63%	-99.98%

03:42pm	Top Premarket Decliners	MT
07-24	Top Premarket Decliners	MT

Market Cap	2.25M 1.97M 1.84M 1.69M 3.17M 215M 3.22M 21.8M 8.53M 107M 8.44M 8.26M 368M	P/E 2025 *	-	P/E 2026	-0.18x
Enterprise Value	-24.95M -21.9M -20.39M -18.75M -35.16M -2.38B -35.76M -242M -94.69M -1.18B -93.67M -91.65M -4.08B	EV / Sales 2025	9.81x	EV / Sales 2026	-22.6x
Free-Float	74.67%	Yield 2025 *	-	Yield 2026	-

03:42pm	Top Premarket Decliners	MT
07-24	Top Premarket Decliners	MT
07-23	Top Premarket Decliners	MT
07-22	Top Premarket Gainers	MT
07-03	China SXT Pharmaceuticals, Inc. announced that it expects to receive $28.56 million in funding	CI
07-02	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
01-08	Top Midday Gainers	MT
01-01	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2025	CI
31/07/25	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2025	CI
28/03/25	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2024	CI
17/03/25	China Sxt Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Requirement	MT
24/01/25	China SXT Pharmaceuticals, Inc. Announces CEO Changes	CI
24/01/25	China SXT Pharmaceuticals, Inc. Announces Board and Committee Changes	CI

07-25	Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)	AQ
07-23	China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering	AQ
07-02	China SXT Pharmaceuticals : Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)	PU
03-24	China SXT Pharmaceuticals, Inc. Announces Share Re-classification	AQ
01-30	China SXT Pharmaceuticals, Inc. Announces Share Consolidation	AQ

China SXT Pharmaceuticals, Inc. Stock

Stocks

SXTC

VGG2161P1650

Pharmaceuticals

Valuation: China SXT Pharmaceuticals, Inc.

Chart: China SXT Pharmaceuticals, Inc.

Latest news : China SXT Pharmaceuticals, Inc.

Analysts' recommendations: China SXT Pharmaceuticals, Inc.

Press Releases: China SXT Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: China SXT Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-17.48%
1 week	-97.63%
Current month	-97.27%
1 month	-97.62%
3 months	-97.23%
6 months	-99.62%
Current year	-99.98%

1 week	0.05	2.39
1 month	0.05	2.93
Current year	0.05	1,046.98
1 year	0.05	1,046.98
3 years	0.05	11,249.94
5 years	0.05	905,981.88
10 years	0.05	1,000,000

Manager	Title	Age	Since
Sze Beng Lim CEO	Chief Executive Officer	-	20/01/2025
Feng Zhou CEO	Chief Executive Officer	34	04/07/2017
Xiaodong Pan DFI	Director of Finance/CFO	49	31/01/2022

Director	Title	Age	Since
Feng Zhou CHM	Chairman	34	04/07/2017
Jun Zheng BRD	Director/Board Member	49	31/12/2018
Xiaodong Ji BRD	Director/Board Member	57	22/05/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHINA SXT PHARMACEUTICALS, INC.	-17.48%	-97.63%	-99.98%	-100.00%	2.25M
ELI LILLY AND COMPANY	+1.93%	+6.43%	+50.20%	+168.28%	1,068B
JOHNSON & JOHNSON	+0.29%	+7.20%	+58.48%	+53.57%	641B
ABBVIE INC.	+2.45%	+3.88%	+38.32%	+76.82%	454B
ROCHE HOLDING AG	+2.17%	+10.91%	+41.94%	+35.03%	351B
NOVARTIS AG	+1.46%	+5.93%	+40.44%	+43.69%	299B
ASTRAZENECA PLC	+0.40%	+4.52%	+19.79%	+20.93%	266B
NOVO NORDISK A/S	+2.73%	+2.26%	-25.81%	-36.98%	220B
AMGEN INC.	+4.48%	+7.94%	+28.22%	+66.53%	203B
GILEAD SCIENCES, INC.	+2.91%	+0.83%	+15.59%	+75.56%	162B
Average	+0.27%	-7.23%	+16.72%	+40.34%	366.33B
Weighted average by Cap.	+1.92%	+2.85%	+39.07%	+81.20%

	2025	2026
Net sales	1.74M 1.53M 1.42M 1.31M 2.45M 166M 2.5M 16.88M 6.61M 82.48M 6.54M 6.39M 285M	1.14M 999K 930K 855K 1.6M 109M 1.63M 11.03M 4.32M 53.92M 4.27M 4.18M 186M
Net income	-3.3M -2.9M -2.7M -2.48M -4.65M -316M -4.73M -32.03M -12.54M -157M -12.4M -12.13M -541M	-6.21M -5.45M -5.07M -4.66M -8.74M -593M -8.89M -60.16M -23.55M -294M -23.3M -22.79M -1.02B
Net Debt	-17.25M -15.14M -14.1M -12.97M -24.31M -1.65B -24.73M -167M -65.47M -817M -64.77M -63.37M -2.82B	-27.2M -23.87M -22.23M -20.45M -38.33M -2.6B -38.98M -264M -103M -1.29B -102M -99.91M -4.45B